Clicky

Compugen Ltd.(CGEN)

Description: Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.


Keywords: Medicine Cancer Biopharmaceutical Life Sciences Immunology Antibodies Treatment Of Cancer Autoimmune Disease Monoclonal Antibodies Rheumatoid Arthritis Antibody Monoclonal Antibody Biomarkers Multiple Sclerosis Therapeutic Products Multiple Myeloma Autoimmunity Monoclonal Antibody Therapy Autoimmune Disorders Immune Disorders Compugen Fusion Protein Treatment Of Multiple Sclerosis Antibody Therapy

Home Page: cgen.com

CGEN Technical Analysis

Azrieli Center
Holon, 5885849
Israel
Phone: 972 3 765 8585


Officers

Name Title
Dr. Anat Cohen-Dayag Ph.D. CEO, Pres & Director
Dr. Oliver Froescheis Ph.D. Sr. VP of Corp. & Bus. Devel.
Dr. Zurit Levine Sr. VP of Technology Innovation
Dr. Henry Adewoye M.D. Sr. VP & Chief Medical Officer
Mr. Alberto Sessa Chief Financial Officer
Ms. Yvonne Naughton Head of Investor Relations & Corp. Communications
Mr. Eran Ben Dor Gen. Counsel & Corp. Sec.
Ms. Dorit Amitay VP of HR
Dr. Yaron Turpaz M.B.A., Ph.D., MBA Sr. VP & Sr. Advisor of Computational Discovery
Rivka Schwartz VP Research and Discovery

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0019
Price-to-Sales TTM: 12.8941
IPO Date: 2000-08-11
Fiscal Year End: December
Full Time Employees: 73
Back to stocks